Kornimate/medical-research-clean huggingface dataset:
effect of pulmonary recruitment maneuver (prm) on pain and nausea after laparoscopic cholecystectomy

Conditions: Pain, Postoperative; Postoperative Nausea and Vomiting

Summary: this prospective, blinded, randomized clinical trial investigates the effect on postoperative pain and nausea, when performing a ventilator-piloted prm at the end of a laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * elective laparoscopic cholecystectomy * american society of anesthesiologists (asa) physical status classification i-ii (with the exception of body mass index over 35 kg/m2) * written consent exclusion criteria: * conversion to open surgery * clavien-dindo grade ≥ ii
a study of lorcaserin as adjunctive treatment in participants with dravet syndrome

Conditions: Epilepsies, Myoclonic

Summary: the primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with dravet syndrome.


Eligibility criteria:
key inclusion criteria: participants must meet all of the following criteria to be included in this study: 1. male or female, age 2 years and older at the time of informed consent 2. diagnosis of epilepsy with dravet syndrome 3. has at least 4 convulsive seizures during the 4 weeks of baseline 4. current treatment with antiepileptic drugs must be stable for at least 4 weeks before screening, and be expected to remain stable throughout the study key exclusion criteria: participants who meet any of the following criteria will be excluded from this study: 1. use of lorcaserin within 4 weeks before screening, or any history of it being discontinued due to lack of efficacy or adverse reactions 2. use of fenfluramine within 2 months before screening, any history of lack of fenfluramine efficacy, or any history of valvulopathy at baseline with history of fenfluramine use 3. recent or concomitant use of serotonergic medications or monoamine oxidase inhibitors 4. presence of progressive central nervous system disease other than dravet syndrome

Keywords: dravet syndrome lorcaserin e2023 epilepsy seizures
can women correctly contract their pelvic floor muscles after to receive verbal instructions and vaginal palpation?

Conditions: Urinary Incontinence; Urinary Incontinence, Stress; Urination Disorders; Lower Urinary Tract Symptoms

Summary: the pelvic floor muscle training (pfmt) is a conservative treatment, currently considered as first line for women with stress urinary incontinence (sui). however, in practice, about 30 to 50% of women are unable to perform the correct contraction of the pelvic floor muscles (pfms). when requested to perform the muscle contraction, the contraction of the gluteal muscles, hip adductors, or abdominal muscles is observed initially, rather of contraction of the levator anus muscle. some factors make it difficult to perform the contraction of the pfm, such as its location on the pelvic floor, and its small size, followed by a lack of knowledge of the pelvic region, as well as its functions. associated with these factors is the use of the muscles adjacent to the pfm, as previously mentioned. in order for women to benefit from a pfmt program for the treatment of sui, the awareness phase of pfm can't be omitted, since the literature is unanimous in stating that pelvic exercises improve the recruitment capacity of the musculature, its tone and reflex coordination during the effort activities.

research questions: the objectives of this study is to test the hypothesis that the provision of verbal instructions about the anatomy and function of pfms associated with the use of body techniques awareness and vaginal palpation helps in learning the correct contraction and improves the function of the pfms. design: a single-centered, double-blind (investigator and outcome assessor) randomised controlled trial with two physiotherapy intervention groups. measurements: the primary outcome measure will be the number of fast muscle fibres, as determined by the number of effective contractions (fast and with full force contraction, 1 second each) out of ten contractions performed. the secondary outcome measure will be the pfm function (vaginal palpation and visual observation), the occurrence of associated contractions of the abdominal, gluteal and adductor muscles during the voluntary contraction of pfm , and self-efficacy scale for practising pfm exercises.

Eligibility criteria:
inclusion criteria: * patients with predominance of sui symptoms and ≥ 2 g leakage measured by pad test and without capability to contract the pfm properly exclusion criteria: * not included if they were younger than 18 years old, had chronic degenerative diseases, pelvic organ prolapse greater than stage i by pop-q, neurologic or psychiatric diseases, ability to contract pfms, had previous pelvic floor re-education programs and/or pelvic floor surgeries

Keywords: urinary incontinence, stress pelvic floor exercise
three anxiolytic drugs used in third molar surgery

Conditions: Dental Anxiety; Impacted Third Molar Tooth

Summary: this study was to compare the effectiveness of three drugs (passiflora incarnata, erythrina mulungum, midazolam) in controlling anxiety in patients undergoing bilateral extraction of asymptomatic, impacted mandibular third molars.

in this research, characterized as a randomized, double-blind, parallel study, 200 healthy volunteered patients aging 18 or older will be distributed into 4 groups (n=50) as follows: group i - 500mg erythrina mulungu; group ii - placebo; group iii ; 100 mg passiflora incarnata; group iv - 15 mg midazolam. all treatments will be administered p.o. 1 hour randomly prior to the surgical procedures. the level of anxiety will be assessed through questionnaires and physical parameters, such as blood pressure, heart rate and oxygen concentration in three periods: at baseline, right before the surgical procedures and after 7 days. data will be collected, tabulated and analyzed by the following statistical tests: chi-square, t-test, anova and tukey test, friedman, fisher's exact test with significance level of 5%.

Eligibility criteria:
inclusion criteria: * indication of bilateral extraction of asymptomatic, impacted mandibular third molars exclusion criteria: * patients under the age of 18 any general health problem based on the medical history and physical examination history of use of any medication within 15 days before the beginning of the research history of hypersensitivity to drugs, substances or materials used in this experiment pregnancy or lactation history of pericoronitis

Keywords: anxiety third molar surgery blood pressure heart rate oxygen saturation
improvement of patient experience and healthcare providers' productivity using virtual reality in the field of radiation therapy

Conditions: Breast Cancer

Summary: the purpose of this study is to investigate the effect of providing information about radiotherapy using virtual reality and to see whether it would improve the productivity of medical staff, improve patient experience and satisfaction, and reduce patient's anxiety prior to radiotherapy.

all patients enrolled in this study will receive the same routine explanation all radiotherapy patients receive currently. however, prior to the routine explanation, additional detailed information regarding radiotherapy (from simulation to treatment) will be given in two different ways. vr arm: the patients who are allocated to the vr arm will receive information about radiotherapy via virtual reality. printed document arm: the patients who are allocated to the printed document arm will receive information about radiotherapy via printed document. patients will answer the questionnaire related to the anxiety scale related to radiotherapy and measure the vital signs such as blood pressure, pulse rate, and the respiratory rate. also, patients will answer the questions about radiotherapy to assess the understanding of radiotherapy and questionnaire on hospital satisfaction.

Eligibility criteria:
inclusion criteria: 1. breast cancer patients who received curative surgery and are planned to receive radiotherapy 2. patients with cognitive abilities to receive virtual reality information 3. patients who are 20 years old or older exclusion criteria: 1. patients who have vision or hearing problems to receive information 2. patients who do not agree to this study 3. pregnancy, fetuses / newborns, minors, and deficient patients 4. 65 years old or older 5. patients who have been treated for dizziness within the last 6 months 6. patients who have experienced severe dizziness within the last 6 months when using electronic devices

Keywords: breast cancer radiotherapy virtual reality
botulinum toxin for chronic neuropathic pain

Conditions: Neuralgia; Chronic Pain

Summary: treatment of peripheral neuropathic pain with botulinum toxin (bont) has showed promising results since the first study was released in 2001. further research, however, is needed in order to strengthen the treatment, and a number of questions are unanswered. this includes which indication is the treatment the most effective, how should the treatment be administered, what is the duration of the effect? this study is a prospective interventional open label study, designed to assess the efficacy and safety of botolinum toxin in the treatment of chronic neuropathic pain.

background: there are eight randomized controlled trials investigating the effectiveness of bont for peripheral neuropathic pain. the indications in the studies include diabetic neuropathy, post-herpetic neuropathy, and peripheral nerve injury. overall, the studies indicate a treatment effect that is significantly better than placebo. however, the studies are relatively small, their outcome measures vary, making comparison difficult, and there is considerable variation in the degree of pain reduction. the duration of the effect of bont treatment varies greatly and has not been systematically studied. the current evidence provides a promising background in the treatment of bont og neuropathic pain, but further research and documentation are needed. at the interdisciplinary pain center, zealand university hospital, bont treatment is already used for patients with neuropathic pain, who do not respond to 1. and 2. line treatments. this study will evaluate the efficacy of the treatment. method: the objective of this study is to prospectively follow a one-year cohort and subsequently conduct a follow-up of 7 months (three treatments) for patients initiating bont treatment. the follow-up includes monitoring the treatment's effectiveness, duration, and recording adverse reactions.

Eligibility criteria:
inclusion criteria: * condition of neuropathic pain verified by paraclinical examination or supported by underlying diseases (e.g., diabetes or herpes zoster). * the condition is characterized by allodynia, hyperalgesia, and/or neuralgiform symptoms such as burning and stabbing pain. * the affected area can be identified through objective examination with detection of disturbances in touch using cotton swabs, pin-prick, and/or vibration exclusion criteria: * mixed etiology of pain not solely attributable to neuropathy (e.g., fibromyalgia and neuropathy or nociceptive pain and neuropathy). * contraindication to bont treatment (allergy to the toxin). * pregnancy. * diseases where bont treatment is contraindicated, such as motor neuron diseases and muscular dystrophy. * severe psychiatric disorder.

Keywords: botulinum toxin chronic pain neuropathic pain
iodine i-131 iodocholesterol, its use in adrenal screening

Conditions: Adrenal Gland Diseases; Adrenal Gland Neoplasms

Summary: this is a clinical research study using i-131 iodocholesterol which is an experimental radioactive chemical that when injected into the vein, is picked up in the adrenal glands and permits visualization with gamma imaging devices. these images are used in diagnosing a variety of adrenal abnormalities.prior to the injection of i-131 iodocholesterol, the patient will receive perchlorate capsules to block any uptake of i-131 by the thyroid gland if this is deemed important. the patient will continue to take these capsules throughout the period of imaging, which may last up to 1 week. the injection of i-131 iodocholesterol will be given into a vein and the patient will return for images on at least 1 and possibly 2 occasions between 3-7 days after injection. if the case requires it, the patient may also be given a steroid in tablet form, dexamethasone, to take orally prior to and after the injection to suppress normal adrenal function so that the abnormal tissues can be more easily detected.


Eligibility criteria:
adults with suspected adrenal disease, such as adrenal adenoma, carcinoma, hyperplasia, or addison's disease.

Keywords: adrenal diseases
lasik using the alcon allegretto wavefront-guided excimer laser vs amo visx wavefront-guided excimer laser

Conditions: Myopia; Astigmatism

Summary: the purpose of the study is to compare the results of lasik surgery when using alcon allegretto wavefront-guided excimer laser system compared to amo visx custom wavefront-guided excimer laser system in patients with nearsightedness with and without astigmatism.

the patients will have a comprehensive eye examination once they express an interest in the study. this includes a slit lamp examination of the front of the eye and a dilated fundoscopic examination of the back of the eye. if there is any pathology noted that would exclude the patient from the study, then we will inform the patient and make an appropriate referral. if the patient is deemed appropriate for the study after a comprehensive examination included computerized videokeratography, then they can be enrolled. the patient will undergo bilateral simultaneous eye surgery. which eye is treated with a wavefront-guided excimer laser and which eye is treated with wavefront-optimized will be randomized so there is a 50% chance for either eye to receive one treatment. the patients will be seen on the day of surgery, post op day one, post op day 4-7, one month, three months, six months and one year. the patient will receive topical antibiotics in each eye for one week following the procedure. lasik treated eyes will receive pred forte 1% ophthalmic drops for one week after treatment. all of this is within the usual and customary standard of care for the treatment of patients undergoing lasik surgery. the research procedures are the least risky that can be performed consistent with sound research design.

Eligibility criteria:
inclusion criteria: * subjects age 21 and older with healthy eyes. * nearsightedness between -0.50 diopters and -7.00 diopters with or without astigmatism of up to 3.50 diopters. exclusion criteria: * subjects under the age of 21. * patients with excessively thin corneas. * patients with topographic evidence of keratoconus. * patients with ectatic eye disorders. * patients with autoimmune diseases. * patients who are pregnant or nursing. * patients must have similar levels of nearsightedness with or without astigmatism in each eye. * they can not be more than 1.5 diopters of difference between eyes. * patients must have similar levels of astigmatism in each eye. * they can not have more than 1.5 diopters of difference in nearsightedness or astigmatism between their two eyes.

Keywords: myopia astigmatism aberrations wavefront lasik wavefront lasik
varenicline effects on cue reactivity and smoking reward/reinforcement

Conditions: Tobacco Dependence

Summary: the purpose of this study was to find out how varenicline works to help people quit smoking. varenicline, also known as chantix™, is an u.s. food and drug administration (fda) approved medication that has been shown to help people quit smoking. this study was trying to evaluate whether varenicline would change the response to smoking and the desire for cigarettes when compared to an inactive placebo control. this was not a quit smoking treatment study, and participants were not asked or required to stop smoking while in this study.

we proposed the following primary hypotheses: 1. tonic (i.e., non-cue-provoked) craving levels would be lower in participants receiving varenicline versus placebo. 2. cue-provoked cravings (self-report and physiological responding) would be lower in participants receiving varenicline versus placebo. (secondary indices of craving include heart rate and skin conductance.) 3. the two primary indices of nicotine reward/reinforcement (mceq and choice index) would be lower in participants receiving varenicline versus placebo. (secondary indices of nicotine reinforcement include smoking topography variables.) a final sample of 100 non-treatment seeking daily smokers were recruited from the tampa-st. petersburg-clearwater metropolitan area via paid advertisements in, and press releases to, local newspapers, as well as targeted outdoor advertising via flyers (e.g., on public transportation). following the screening session, participants were randomly assigned to receive either varenicline or placebo medication.

Eligibility criteria:
inclusion criteria: * 18-60 years of age * smoke at least 15 cigarettes daily * expired-air carbon monoxide (co) \> 10 ppm * medically eligible to receive varenicline. exclusion criteria: * patients who are pregnant or lactating * who show evidence of renal dysfunction (bun \> 25 mg/dl, or creatinine \> 1.3 mg/dl) * are using other smoking cessation medications * have current psychiatric disorders (i.e. major depression, manic depression, and/or psychotic episodes) as determined by the structured clinical interview for dsm disorders (scid) (first et al., 1996), will be excluded

Keywords: tobacco nicotine smoking reward reinforcement craving cues conditioned stimuli cue reactivity
blue-green space physical activity: the "parco del mare" study

Conditions: Healthy Adults; Natural Outdoor Environment; Health Promotion

Summary: this study protocol, describe the innovative study intervention which will be performed in a green-blue space in italy in order to investigate on the improvements in wellbeing following participation in the study. this will be significant because it will provide evidence on the effectiveness of the supervised physical activities carried out in green-blue space in improving health, quality of life, physical performance, anthropometric outcomes and physiological parameters in adults, indicating the reasonableness for public health authorities to developing such activities.

the aim of the "parco del mare" pilot study is to evaluate the feasibility and the effects of a moderate-intensity exercise program carried out in a green-blue space, on health outcomes such as quality of life and physical performance. healthy adults with no contraindication to practice physical activity will be recruited and divided into two groups: the experimental group involved in the exercise sessions performed twice a week for 6-months, while the control group received no intervention. validated tests and questionnaires will be used to detect health parameters at baseline (t0) and follow-up (t1). the investigators expected the intervention carried out in the parco del mare setting to be feasible and effective in improving health parameters, quality of life and physical performance in healthy adults.

Eligibility criteria:
inclusion criteria: * adult population aged \>18 years old * resident in rimini exclusion criteria: * any alterations in communication skills and/or sensory functions so severe as to make it impossible to understand and/or execute the instructions given by the trainer (dementia, aphasia, blindness, deafness)

Keywords: blue-green space setting physical activity intervention outdoor exercise public health
safety and efficacy of zevalin in the treatment of non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to provide treatment for patients who have relapsed nhl or refractory nhl, and to determine the effectiveness and safety of the zevalin and rituxan regimens or rituxan therapy alone on your disease.


Eligibility criteria:
summary of major inclusion and exclusion criteria. other safety criteria will need to be met. inclusion criteria: * histologically confirmed, relapsed or refractory cd20+ follicular b-cell nhl within 12 months of study day 1 (without clinical evidence of transformation). nhl must require treatment as determined by an increase in overall tumor size. the presence of b symptoms, and/or the presence of masses which are causing ongoing clinical symptoms. * bidimensionally measurable disease meeting the minimum requirement of at least 1 lesion \>/= 2.0 cm in a single dimension. * no lymphoma therapy for 3 weeks prior to study day 1. * patients must be recovered from all toxicities associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy. * signed irb-approved informed consent. * greater than 18 years of age. * expected survival \>/= 3 months. * who performance status of \</= 2. * acceptable hematologic status, liver function, renal function, and pulmonary function. * female patients who are not pregnant or lactating. * men and women of reproductive potential who are following accepted birth control methods. exclusion criteria: * patients with impaired bone marrow reserve, which may be indicated by prior myeloablative therapy with autologous bone marrow transplantation (abmt) or peripheral blood stem cell (pbsc) rescue. * prior radioimmunotherapy, including the zevalin regimen. * prior immunotherapy, including rituxan therapy within 6 months of study day 1. * rituxan-refractory (no response to most recent rituxan-containing regimen, or ttp was \< 6 months). * presence of cns lymphoma. * patients with chronic lymphocytic leukemia (cll). * known history of hiv or aids. * serious nonmalignant disease or infection * major surgery, other than diagnostic surgery, within 4 weeks of study day 1. * patients who received investigational product within 4 weeks of study day 1 or patients who may experience long-term toxicity from a previous investigational therapy.
characterization of the cardiac reinnervation of patients with transposition of the great arteries long after repair with the arterial switch operation. correlation with electrocardiographic and exercise test parameters

Conditions: Congenital Heart Disease; Congenital Heart Defect; Transposition of the Great Arteries

Summary: cardiac denervation is inherent to the arterial switch (aso) technique for the repair of transposition of the great arteries (tga) and the long term reinnervation process has not been studied. we sought to describe the reinnervation status of adult patients long after the aso, to identify areas of myocardial perfusion/innervation mismatch and to assess the relation of innervation status and exercise capacity.

cardiac denervation is inherent to the arterial switch (aso) technique for the repair of transposition of the great arteries (tga) and the long term reinnervation process has not been studied. we sought to describe the reinnervation status of adult patients long after the aso, to identify areas of myocardial perfusion/innervation mismatch and to assess the relation of innervation status and exercise capacity.

Eligibility criteria:
inclusion criteria: * patients with transposition of the great arteries repaired with the arterial switch. * patients aged of more than 18 years-old. exclusion criteria: * pregnancy or breast-feeding. * denial of informed consent.

Keywords: congenital heart disease cardiac denervation 123i-metaiodobenzylguanidine arterial switch operation